TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1795055
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine gluconate (CHX) solution
Study: 1795055
Drug: 0.025% amine‐stannous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% amine‐stannous fluoride (AmF + SnF) solution
Study: 1795055
Drug: 0.05% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% sodium fluoride (F) solution
Study: 7236870
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg oral dose of 'Inderal' tablet (conventional formulation)
Study: 7236870
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release formulation 'Inderal' LA
Study: 7236870
Drug: Clinical trial
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical trial sustained release formulation
Study: 7236870
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release formulations (both)
Study: 25943394
Drug: Metformin (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (with supplemental insulin if required)
Study: 22509859
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 70/30 (BIAsp 30)
Study: 19095875
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL saline (control group)
Study: 19095875
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tramadol and 2 mL saline (TL group)
Study: 7029292
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with Adriamycin and cyclophosphamide (Cytoxan) in soft tissue sarcomas
Study: 7029292
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate following surgery in osteogenic sarcoma
Study: 31758920
Drug: Drospirenone (DRSP)
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone (DRSP) 4 mg
Study: 27596027
Drug: Web-based physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based physiotherapy (8 weeks, twice per week)
Study: 25245489
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium 100 mg once daily
Study: 25245489
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium 100 mg three times daily
Study: 23588794
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan injection (6 mg)
Study: 31622374
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg D-cycloserine (DCS)
Study: 21301814
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg D-cycloserine (DCS) with partial smoking
Study: 18973950
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with intravenous verteporfin at 6 mg/m² body surface, laser beam applied at radiant exposure 50 J/cm² for 83 seconds, 1 to 4 treatments at 12-week intervals over 1 year.
Study: 11770871
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment for > or = 6 months before hospital admission
Study: 8077738
Drug: 1 day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day of parenteral clindamycin (standard prophylaxis)
Study: 8077738
Drug: 1 day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day of topical clindamycin
Study: 8077738
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of topical clindamycin
Study: 8077738
Drug: 1 day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day of topical amoxicillin plus clavulanate/ticarcillin plus clavulanate
Study: 28719305
Drug: Monthly visits
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly visits from sales agents
Study: 26272768
Drug: Rolapitant (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolapitant (180 mg dose)
Study: 7044294
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of chlorpheniramine
Study: 22719016
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of chlorpheniramine-200 mg of caffeine
Study: 21754985
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) and L-carnitine for 12 months
Study: 11782819
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg valdecoxib twice daily
Study: 11782819
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg valdecoxib twice daily
Study: 8590611
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) 100 mg, PO, tid
Study: 8590611
Drug: Standard detoxification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard detoxification therapy
Study: 8590611
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) 50-100 mg, bid-tid after acute withdrawal
Study: 2492178
Drug: Bilateral myringotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral myringotomy and no additional treatment (group 1)
Study: 1091151
Drug: Adenine arabinoside
Normalized name: Adenine
DrugBank: Adenine (DB00173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenine arabinoside 20 mg/kg/day intravenous infusions for seven days
Study: 27281720
Drug: Intraneural injection
Normalized name: bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraneural injection (group INTRA)
Study: 27281720
Drug: Subparaneural injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subparaneural injection (group SUBPARA)
Study: 15485437
Drug: Digitalis and
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis and beta-blocker during isoproterenol infusion
Study: 9753263
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg twice daily for six months
Study: 7826831
Drug: 97 mg
Normalized name: kaolin 197 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 97 mg amoxycillin sodium (0.25 mmol)
Study: 7826831
Drug: 3103 mg
Normalized name: Mg
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3103 mg amoxycillin sodium (8 mmol)
Study: 30197311
Drug: Verapamil injection
Normalized name: verapamil Injection
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil injection (2 mL) around the anastomosis site before and after surgery (2, 4, 6, 8, and 10 weeks after surgery)
Study: 27185164
Drug: FP/FORM (100/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/FORM (100/10 µg b.i.d.)
Study: 27185164
Drug: FP/SAL (100/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/SAL (100/50 µg b.i.d.)
Study: 24190232
Drug: MSUS-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSUS-guided injection of 40 mg of methylprednisolone acetate (Group 2, n = 59)
Study: 24190232
Drug: Palpation-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation-guided injection (Group 1, n = 66)
Study: 18717680
Drug: 5-aminolaevulinic acid-photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-aminolaevulinic acid-photodynamic therapy (ALA-PDT)
Study: 16282192
Drug: Cannabis-based medicine
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis-based medicine (Sativex)
Study: 1389816
Drug: 0.5% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% plain bupivacaine administered at a speed of 10 seconds
Study: 1389816
Drug: 0.5% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% plain bupivacaine administered at a speed of 180 seconds
Study: 26626719
Drug: Once-daily tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tobramycin inhalation solution (TIS) 300 mg/5 mL
Study: 26626719
Drug: Twice-daily tobramycin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily tobramycin inhalation solution (TIS) 300 mg/5 mL
Study: 26626719
Drug: Once-daily versus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily versus twice-daily tobramycin inhalation solution (TIS)
Study: 26626719
Drug: Both once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both once-daily and twice-daily tobramycin inhalation solution (TIS)
Study: 24960387
Drug: Listerine Cool
Normalized name: Listerine Cool Mint Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listerine Cool Blue Agent
Study: 1977330
Drug: Sufentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (1 microgram/kg) and Vecuronium (0.2 mg/kg)
Study: 1977330
Drug: Sufentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (1 microgram/kg) and Atracurium (1.0 mg/kg)
Study: 1977330
Drug: Fentanyl (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (5 micrograms/kg) and Vecuronium (0.2 mg/kg)
Study: 1977330
Drug: Fentanyl (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (5 micrograms/kg) and Atracurium (1.0 mg/kg)
Study: 31862277
Drug: Jacobson's relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jacobson's relaxation technique (20‐30min daily for three consecutive days)
Study: 31862277
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care and treatment (control group)
Study: 30087153
Drug: 10 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg fluid bolus every 15 min for up to 4 hours
Study: 30087153
Drug: 20 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/kg fluid bolus every 15 min for up to 4 hours
Study: 25741969
Drug: Short-course ARV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course ARV (antenatal zidovudine with single-dose nevirapine)
Study: 23506731
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER (4 mg) daily
Study: 20021912
Drug: 0.15 U/(kg.d)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 U/(kg.d) growth hormone (Somatropin, S19990021) in A(1) and B(1) groups
Study: 20021912
Drug: 0.2 U/(kg.d)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 U/(kg.d) growth hormone in A(2) and B(2) groups
Study: 20021912
Drug: No growth
Normalized name: Mechano growth factor
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: No growth hormone (NS) in A(0) and B(0) groups
Study: 20021912
Drug: 0.15 U/(kg.d)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 U/(kg.d) growth hormone in A(1) and B(1) groups
Study: 9120921
Drug: Fat injections
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat injections
Study: 9120921
Drug: Collagen injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen injections
Study: 8443252
Drug: Weekly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly telephone survey
Study: 3537462
Drug: Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Therapy (N = 10)
Study: 29030503
Drug: Blended therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended therapy
Study: 31419322
Drug: DTPw (cellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw (cellular Bordetella pertussis vaccine)
Study: 31419322
Drug: DTPa (acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa (acellular Bordetella pertussis vaccine)
Study: 26409158
Drug: Acceptance &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance & Commitment Therapy (ACT)
Study: 21300246
Drug: Inadequate pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inadequate pretreatment oral hygiene
Study: 19741484
Drug: Propofol (0-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0-12 microg/ml) and Sevoflurane (0-3.5 vol.%)
Study: 19741484
Drug: Propofol (0-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0-12 microg/ml)
Study: 11352440
Drug: Moxifloxacin 400mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin 400mg administered orally after 250g of yoghurt
Study: 11352440
Drug: Moxifloxacin 400mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin 400mg administered orally under fasting conditions
Study: 8200006
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose dactinomycin (60 mcg/kg x 1 day)
Study: 8200006
Drug: Standard fractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fractionated dactinomycin (15 mcg/kg x 5 days)
Study: 2965631
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion at 0.4 pmol min-1 kg-1
Study: 2965631
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion at 2 pmol min-1 kg-1
Study: 2965631
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion at 10 pmol min-1 kg-1
Study: 24640666
Drug: levofloxacin (Glevo)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: levofloxacin (Glevo) 500 mg/day
Study: 24640666
Drug: original levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: original levofloxacin 500 mg/day
Study: 19178516
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR 20 mg every 28 days
Study: 15538079
Drug: Oral antioxidants
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antioxidants (oxygenated carotenoid - lutein)
Study: 9642972
Drug: Clonazepam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (1.5 to 3 mg daily)
Study: 2954800
Drug: Partially purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially purified bovine/porcine insulin
Study: 23902631
Drug: Active deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active deep brain stimulation to the ventral striatum/anterior limb of the internal capsule
Study: 20570290
Drug: Cefazolin continuous
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin continuous infusion (1 g every 6 hours for 18 hours after an initial 2 g dose)
Study: 20570290
Drug: Cefazolin intermittent
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin intermittent administration (1 g at 3, 9, and 15 hours after an initial 2 g dose)
Study: 20570290
Drug: Cefazolin continuous
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin continuous infusion
Study: 20570290
Drug: Cefazolin intermittent
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin intermittent administration
Study: 12124550
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg orally every 8 hours
Study: 12124550
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no steroids or NSAIDs)
Study: 9585797
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day ipsapirone CR
Study: 9585797
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day fluoxetine
Study: 7635364
Drug: Intrauterine insemination
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine insemination (IUI) with 0.5 ml of inseminate
Study: 7635364
Drug: Fallopian sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fallopian sperm perfusion (FSP) with 4 ml of inseminate
Study: 408844
Drug: l-amphetamine 10
Normalized name: amphetamine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-amphetamine 10 mg
Study: 31013226
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg daily for up to 5 days before surgery)
Study: 31013226
Drug: Medication-free group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-free group (no aspirin)
Study: 30158152
Drug: Tenapanor (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor (15 mg, given twice daily for 4 days)
Study: 24569916
Drug: Neoadjuvant cisplatin‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant cisplatin‐based combination chemotherapy
Study: 24569916
Drug: Cystectomy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystectomy alone or surgery followed by adjuvant chemotherapy
Study: 23230999
Drug: Doxylamine hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxylamine hydrogen succinate 25 mg under fed conditions
Study: 23230999
Drug: Doxylamine hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxylamine hydrogen succinate 25 mg under fasting conditions
Study: 10568115
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (Duraflo II, n = 20)
Study: 8911631
Drug: IVIG infusions
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG infusions (200-250 mg/kg) every 3 weeks during the first 8 months of pregnancy
Study: 1868270
Drug: Synthetic hPTH
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic hPTH (1‐38) for the first 14 days of a 100 day cycle, followed by no other therapy (Group 1)
Study: 1868270
Drug: Synthetic hPTH
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic hPTH (1‐38) for the first 14 days of a 100 day cycle followed by salmon calcitonin at an average dose of 79 units per day for a 56 day depressor period (Group 2)
Study: 31711671
Drug: Digoxin administered
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin administered intraamniotically or intrafetally prior to second-trimester surgical abortion
Study: 29863842
Drug: Onion-ring-like g-C3N4
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion-ring-like g-C3N4
Study: 29863842
Drug: Bulk g-C3N4
Normalized name: psyllium
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk g-C3N4
Study: 23534333
Drug: RPE treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPE treatment (n = 12)
Study: 17437965
Drug: Cinitapride (CTP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinitapride (CTP; 1 mg t.i.d.) + ketoconazole (KET; 200 mg b.i.d.)
Study: 17437965
Drug: Cinitapride (CTP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinitapride (CTP; 1 mg t.i.d.) + placebo (PL)
Study: 17437965
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) + ketoconazole (KET; 200 mg b.i.d.)
Study: 15362028
Drug: Mesalamine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine (3 g/day)
Study: 25919835
Drug: Increase to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase to 30 mg/d of mirtazapine (increase(30) group)
Study: 25919835
Drug: Maintain at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintain at 15 mg/d of mirtazapine (stay(15) group)
Study: 25919835
Drug: Increase to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase to 45 mg/d of mirtazapine (increase(45) group)
Study: 25919835
Drug: Maintain at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintain at 30 mg/d of mirtazapine (stay(30) group)
Study: 22961272
Drug: Local injections
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injections of rhGH
Study: 19773751
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by adjuvant chemotherapy
Study: 17706059
Drug: Reduced osmolarity
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced osmolarity oral rehydration salts (ROORS)
Study: 17706059
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salts II (ORS II)
Study: 15045139
Drug: IGIV-C (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-C (1 g/kg/day for 2 days)
Study: 15045139
Drug: IGIV-S/D (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-S/D (1 g/kg/day for 2 days)
Study: 7493311
Drug: rIFN-alpha 3
Normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-alpha 3 MU thrice weekly (group A)
Study: 7493311
Drug: rIFN-alpha 6
Normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-alpha 6 MU thrice weekly (group B)